Therapeutics News and Research

RSS

Simple blood test could identify the most effective obesity drug

Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, enhancing personalized therapy.

29 Jun 2026

New screening approach identifies proteins that control human gene expression

Researchers at University of California San Diego have developed a large-scale screening approach that identifies proteins controlling a fundamental step in gene expression known as alternative polyadenylation (APA).

26 Jun 2026

Engineered CAR T cells successfully target bladder cancer in mice

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells.

26 Jun 2026

Lactate and lactylation play multifaceted roles in pancreatic ductal adenocarcinoma

A comprehensive review recently published in Current Molecular Pharmacology illuminates the pivotal, multifaceted roles of lactate and its downstream protein modification, lactylation, in pancreatic ductal adenocarcinoma (PDAC).

25 Jun 2026

Merck KGaA, Darmstadt, Germany, agrees to acquire Bio-Techne, strengthening leadership position in fast-growing life sciences markets

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price.

From Bio-Techne 25 Jun 2026

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

25 Jun 2026

Scientists identify genes linking air pollution to severe asthma

For many people with asthma, air-quality advisories are harbingers of worsening symptoms. But for reasons science has struggled to explain, the extent to which pollution exacerbates asthma varies widely from person to person.

24 Jun 2026

Natural microbial compound helps protect the gut from chronic inflammation

University of Louisville researchers have discovered how a naturally occurring microbial compound may help protect the gut and support future treatment strategies for inflammatory bowel disease (IBD).

24 Jun 2026

Researchers uncover key mechanism driving chronic Sjögren disease

Sjögren disease, an autoimmune disease characterized by dry mouth and dry eyes, may reduce patients’ quality of life.

24 Jun 2026

FairJourney Bio and AbTherx partner to offer fully integrated antibody discovery

FairJourney Bio (“FJBio”), a global antibody discovery expert, has entered a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the Company access to AbTherx’s Atlas™ Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies, completing a discovery route that partners can now run end to end entirely within FJBio’s integrated workflow.

From FairJourney Biologics S.A. 24 Jun 2026

Study uncovers sex-specific immune pathway driving glioblastoma growth

Researchers have identified a critical biological difference in how glioblastoma develops in male and female laboratory models, pinpointing an immune pathway that fuels tumor growth only in females.

23 Jun 2026

Researchers identify molecular cause of age-related cognitive decline

A research team from University Hospitals, Case Western Reserve University and the Louis Stokes Cleveland VA Medical Center has identified a critical molecular cause of age-related cognitive decline, potentially paving the way for new treatments to protect brain health as we age.

23 Jun 2026

TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio

TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million).

From TRIMTECH Therapeutics 23 Jun 2026

Using the mathematics of quantum mechanics to improve neuroblastoma outcomes

For a child diagnosed with neuroblastoma-the most common infant cancer, occurring when early nerve cells grow out of control-the path to treatment isn't simple.

22 Jun 2026

Mount Sinai study connects social determinants of health to disease risks

A new study from the Icahn School of Medicine at Mount Sinai shows that social determinants of health-including environmental conditions, health behaviors, access to resources, and social well-being-can play an equally important or even greater role than genetics in predicting a person's risk of developing common diseases.

22 Jun 2026

Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802

Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company's lead therapeutic candidate.

From Pheno Therapeutics 22 Jun 2026

Synthetic gut communities reveal how diet rewires the microbiome

Synthetic microbial communities give researchers controlled models for testing how diet reshapes gut microbial ecology, metabolism, and host-relevant responses. The review highlights how SynComs can strengthen causal inference, improve intervention testing, and support future precision nutrition, while noting major challenges in stability, standardization, and ecological realism.

21 Jun 2026

New method generates renewable supply of progenitor immune cells

In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages.

19 Jun 2026

Scientists discover rotating brain waves that coordinate sensory information

Spiraling waves of neural activity appear and travel in the brain. Scientists hope to learn if these rotating waves on-the-move play a global role in sensing and interpreting internal and external stimuli, in laying down memory, and in managing motor performance.

18 Jun 2026

WHO Issues Comprehensive Guidelines On Filovirus Disease, Including Ebola And Marburg Disease

As the Democratic Republic of the Congo is battling an Ebola disease outbreak caused by the Bundibugyo virus, the World Health Organization (WHO) has released its first comprehensive guidelines for the clinical management of filovirus disease which include all types of Ebola and Marburg viruses.

18 Jun 2026